GLMD — Galmed Pharmaceuticals Income Statement
0.000.00%
- $1.75m
- -$9.06m
- 29
- 58
- 23
- 29
Annual income statement for Galmed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 22.4 | 30.2 | 32.9 | 17.7 | 7.49 |
Operating Profit | -22.4 | -30.2 | -32.9 | -17.7 | -7.49 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.5 | -28.8 | -32.5 | -17.9 | -6.91 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.5 | -28.8 | -32.5 | -17.9 | -6.91 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.5 | -28.8 | -32.5 | -17.9 | -6.91 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.5 | -28.8 | -32.5 | -17.9 | -6.91 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -14.5 | -20.3 | -19.8 | -10.7 | -2.5 |